Clinical Trial Detail

NCT ID NCT02709083
Title Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Emory University
Indications

chronic myeloid leukemia

Therapies

Dasatinib

Nilotinib

Imatinib

Age Groups: adult

Additional content available in CKB BOOST